Reports Q3 revenue $48M, consensus $37.56M. “Through the course of this year, we have presented multiple compelling datasets at medical conferences that we believe have de-risked several programs and support potential best-in-class profiles for our molecules, including our HIF-2a inhibitor casdatifan in ccRCC and our Fc-silent anti-TIGIT antibody domvanalimab in lung and upper gastrointestinal cancers,” said Terry Rosen, Ph.D., chief executive officer of Arcus. “Meanwhile, in addition to our rapidly approaching first Phase 3 readout for domvanalimab in gastric cancer, we are aggressively pursuing our development plan for casdatifan, including in the IO-naive ccRCC setting in collaboration with AstraZeneca, and in the post-IO setting with the initiation of our Phase 3 PEAK-1 study in the first half of next year.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RCUS:
- Arcus Biosciences announces results from Part 1 of ARC-10 trial
- Arcus Biosciences price target raised to $29 from $25 at Barclays
- Arcus Biosciences Reports Promising Trial Results
- Arcus Biosciences price target raised to $46 from $38 at Citi
- Arcus: HIF-2a inhibitor, casdatifan data ‘shows promise’ in ccRCC treatment
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
